We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aram... Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Show more
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis PR Newswire TEL AVIV, Israel, March 15...
CUSIP No: M47238122 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN...
As filed with the Securities and Exchange Commission on November 22, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or...
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study PR Newswire TEL AVIV, Israel, Nov. 20, 2023 TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/...
As filed with the Securities and Exchange Commission on November 1, 2023. Registration No. 333-272722 UNITED STATES SECURITIES AND EXCHANGE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0343 | 11.2459016393 | 0.305 | 0.349 | 0.302 | 65517 | 0.31823587 | CS |
4 | -0.073 | -17.7055542081 | 0.4123 | 0.4299 | 0.3 | 240024 | 0.3211906 | CS |
12 | -0.0907 | -21.0930232558 | 0.43 | 0.4688 | 0.3 | 149735 | 0.3484419 | CS |
26 | -0.2514 | -42.5596749619 | 0.5907 | 0.8749 | 0.26 | 174375 | 0.38899663 | CS |
52 | -6.1107 | -94.7395348837 | 6.45 | 7.8 | 0.26 | 214813 | 2.19923076 | CS |
156 | -51.4107 | -99.3443478261 | 51.75 | 61.2 | 0.26 | 167606 | 18.81206226 | CS |
260 | -122.0607 | -99.7227941176 | 122.4 | 140.55 | 0.26 | 151728 | 36.87618606 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions